25 January 2021 - 88% of patients on Calquence remained free of disease progression after 12 months vs. 68% for comparators.
AstraZeneca’s Calquence (acalabrutinib), a next-generation, selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in Japan for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia (including small lymphocytic lymphoma).